| License: Creative Commons Attribution 4.0 PDF - Published Version (403kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-460089
- DOI to cite this document:
- 10.5283/epub.46008
Abstract
Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment option for many patients with hematological disorders but it includes a significant risk of mortality and long-term morbidity. Many patients and their support persons feel overwhelmed when being informed about alloHSCT and may benefit from improvements in consultation style and ...

Owner only: item control page